Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus

被引：323

作者：

Cui, LZ

Tominaga, E

Neoh, HM

Hiramatsu, K

机构：

[1] Juntendo Univ, Fac Med, Dept Bacteriol, Bunkyo Ku, Tokyo 1138421, Japan

[2] Juntendo Univ, Fac Med, Dept Infect Control Sci, Bunkyo Ku, Tokyo 1138421, Japan

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2006年 / 50卷 / 03期

关键词：

D O I：

10.1128/AAC.50.3.1079-1082.2006

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We present here findings of a strong positive correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus (VISA). This correlation is related to cell wall thickening, suggesting that, similar to the case with vancomycin resistance in VISA, the physical barrier of a thickened cell wall may contribute to daptomycin resistance in S. aureus.

引用

页码：1079 / 1082

页数：4

共 50 条

[31] Survival of vancomycin-intermediate Staphylococcus aureus on hospital surfaces
Zarpellon, M. N.
Gales, A. C.
Sasaki, A. L.
Selhorst, G. J.
Menegucci, T. C.
Cardoso, C. L.
Garcia, L. B.
Tognim, M. C. B.
JOURNAL OF HOSPITAL INFECTION, 2015, 90 (04) : 347 - 350
[32] Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions
Moise, Pamela A.
North, Donald
Steenbergen, Judith N.
Sakoulas, George
LANCET INFECTIOUS DISEASES, 2009, 9 (10): : 617 - 624
[33] Biofilms: A developmental niche for vancomycin-intermediate Staphylococcus aureus
Chapman, Jenelle E.
George, Shilpa E.
Wolz, Christiane
Olson, Michael E.
INFECTION GENETICS AND EVOLUTION, 2024, 117
[34] First case report of vancomycin-intermediate sequence type 72 Staphylococcus aureus with nonsusceptibility to daptomycin
Tsukimori, Ayaka
Nakamura, Itaru
Okamura, Sakiko
Sato, Akihiro
Fukushima, Shinji
Mizuno, Yasutaka
Yamaguchi, Tetsuo
Matsumoto, Tetsuya
BMC INFECTIOUS DISEASES, 2014, 14
[35] Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF
Pillai, Satish K.
Gold, Howard S.
Sakoulas, George
Wennersten, Christine
Moellering, Robert C., Jr.
Eliopoulos, George M.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (06) : 2223 - 2225
[36] Serial Daptomycin Selection Generates Daptomycin-Nonsusceptible Staphylococcus aureus Strains with a Heterogeneous Vancomycin-Intermediate Phenotype
Camargo, Ilana Lopes Baratella da Cunha
Neoh, Hui-Min
Cui, Longzhu
Hiramatsu, Keiichi
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (12) : 4289 - 4299
[37] Development of Daptomycin Nonsusceptibility with Heterogeneous Vancomycin-Intermediate Resistance and Oxacillin Susceptibility in Methicillin-Resistant Staphylococcus aureus during High-Dose Daptomycin Treatment
Lee, Chen-Hsiang
Wang, Ming-Chung
Huang, I-Wen
Chen, Feng-Jui
Lauderdale, Tsai-Ling
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (09) : 4038 - 4040
[38] Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates
Zhang, Shanshan
Sun, Xiaoxi
Chang, Wenjiao
Dai, Yuanyuan
Ma, Xiaoling
PLOS ONE, 2015, 10 (08):
[39] Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus
Aeschlimann, JR
Hershberger, E
Rybak, MJ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) : 1914 - 1918
[40] sarA inactivation reduces vancomycin-intermediate and ciprofloxacin resistance expression by Staphylococcus aureus
Lamichhane-Khadka, Reena
Cantore, Stephanie A.
Riordan, James T.
Delgado, Alejandro
Norman, Alesha E. A.
Duenas, Sarah
Zaman, Shahrear
Horan, Sonia
Wilkinson, Brian J.
Gustafson, John E.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 34 (02) : 136 - 141

← 1 2 3 4 5 →